template-parts/default.php
Single-Dose Drug Delivery Fill-Finish Facility that is Scalable, Flexible, and able to Deliver up to 45M Units Per Month Delivered within an Accelerated Timeline of Fewer Than 7 Months
Part 3 of Pharmaceutical Technology Post-Webinar Series
ApiJect committed to creating emergency temporary fill-finish capacity for up to 45M doses a month of a candidate COVID-19 vaccine on BFS lines by the end of 2020. All of these BFS-packaged doses could then be used, if necessary, in ApiJect Prefilled Injectors for scalable, single-dose delivery.
template-parts/default.php
Solving Drug Challenges with Innovation, BFS, and a Technology Platform to Create Drug
Delivery Systems
Part 2 of Pharmaceutical Technology Post-Webinar Series
Learn how ApiJect built its Technology Platform around BFS to create innovative drug delivery systems for the prefilled syringe market and other sterile liquid pharmaceutical delivery formats.
template-parts/default.php
BFS and Prefilled Syringes: A Solution for Complex Formulations
Part 1 of Pharmaceutical Technology Post-Webinar Series
Many countries, including the US, lack the necessary surge capacity to reliably fill-finish and deliver billions of incremental doses of injectable drugs and vaccines during bio-emergencies.
template-parts/default.php
Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market
Drug Development & Delivery, Issue: May 2021
Worldwide, the parenteral market is seeing greater emphasis on patient safety. This is driving a strong trend toward unit-dose formats, including Blow-Fill-Seal prefilled syringe, which are now the fastest-growing format for injectables.
